HIGHLIGHTS
- who: Eosinophilia Benralizumab and colleagues from the Division of Allergology and Clinical Immunology, Bern University Hospital, University of Bern, Bern, Switzerland have published the paper: Treatment with IL5-/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS), in the Journal: (JOURNAL)
- what: The aim of this study is to summarize current experience with the anti-IL5/IL-5-receptor therapy in DRESS. Based on the reported cases, the authors propose a use of an IL5/IL-5R blockade in the following situations : Duration of treatment - Recommendation of 3 months at 4 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.